Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis

Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis

Abstract Background Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia. This study aims to estimate its cost-effectiveness and budget i...

Full description

Bibliographic Details
Main Authors: Septiara Putri, Ery Setiawan, Siti Rizny F. Saldi, Levina Chandra Khoe, Euis Ratna Sari, Amila Megraini, Mardiati Nadjib, Sudigdo Sastroasmoro, Armansyah Armansyah
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Health Services Research
Subjects:
Rituximab
Lymphoma
DLBCL
Cost-effectiveness
Online Access:https://doi.org/10.1186/s12913-022-07956-w

Internet

https://doi.org/10.1186/s12913-022-07956-w

Similar Items